Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.
Semaglutide Acetate is a long-acting GLP-1 analogue with GLP-1 receptor affinity of 0.38 nM.
Semaglutide Acetate improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. Semaglutide Acetate rescues the decrease of tyrosine hydroxylase (TH) levels, reduces lipid peroxidation, inhibits the apoptosis pathway, alleviates the inflammation response, increases autophagy-related protein expression, and protects dopaminergic neurons in the substantia nigra and striatum. In mini-pigs, The plasma half-life of Semaglutide Acetate (i.v.) is 46h and the MRT of Semaglutide Acetate (s.c.) is 63.6h.